Form Approve

OMB No: 0920-xxxx

Exp. Date: xx-xx-xxxx

The public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to—CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333 ATTN: PRA (0920-XXXX)

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

 **ORS Annual Evaluation Survey- Public Health Partner**

Thank you for participating in this brief survey about your participation in the Overdose Response Strategy (ORS) program. With this annual survey, we are seeking to understand the components of partnership, networks and mutually reinforcing activities that lead to shared, effective efforts to reduce drug overdoses and save lives. The results will be used to measure the progression and impacts of this unique partnership. We’re asking that you respond to the questions based on how the ORS program operated in 2024. The survey will take approximately 30 minutes to complete, and your responses are completely anonymous. The data collected from this survey will be summarized and no individual person will be identifiable from the summarized results. If you have questions or need help with the survey, please contact ***ORSperformance@cdcfoundation.org***. We truly value your experience and feedback!

1. When did your jurisdiction join the ORS program?
* 2 years or less
* 3-5 years
* More than 5 years (before 2020)
1. Have you been in your role with the ORS for 6 or more months? Yes or No

**“Backbone” Support from the ORS Program**

The ORS was created to help local communities reduce drug overdoses and save lives by sharing timely data, pertinent intelligence and evidence-based and innovative strategies. For the following questions, select the option that best describes to what extent you agree with the statement for the ORS program as it operated in 2024.

1. The ORS program builds a common understanding of the problem that needs to be addressed.
2. The ORS program builds and maintains motivation among key stakeholders to achieve the program’s goals.
3. The ORS program provides support toward identified goals and opportunities, and identifies challenges and gaps.
4. The ORS program understands how local context influences implementation of ORS goals.
5. The ORS program is committed to and actively involved in achieving our state/jurisdiction goals.
6. As a result of the involvement with the ORS program, public health and public safety collaboration and communication in my state/jurisdiction is stronger.
7. As a result of the involvement with the ORS program, our state/jurisdictional efforts can better address overdoses.

**Partner Relationships/Attributes**

1. My organization has clear approaches/goals for our contributions to the ORS program.
2. My organization understands the work of other ORS partners in my state/jurisdiction and how they support the common goals of the ORS program.

**For the following questions, select the option that best describes to what extent you agree with the statement for the HIDTA that you are partnered with as it operated in 2024.**

1. My public safety partner works collaboratively to identify and implement strategies.
2. My public safety partner takes part in activities to build trust and connection across sectors.
3. My public safety partner engages in frank, open and respectful discussion specifically about each other’s needs and/or priorities as it relates to the ORS.
4. My public safety partner is committed to and actively involved in achieving our state/jurisdictional ORS program goals.
5. Indicate the best fit for the current level of involvement with your ORS public safety partner from your perspective.
6. Identify your desired level of involvement with this partner.
7. If you are not at your desired level of collaboration, what characteristics would need to change to reach it?
8. Our involvement with this public safety partner has improved my organization’s approach to addressing overdoses.

**Local Implementation of the ORS partnership model**

For the following questions, select the option that best describes to what extent you agree with the statement for your organization and your ORS state/jurisdiction partners as it operated in 2024.

1. The state/jurisdictional ORS Action Plan captures the shared priorities for the ORS team in my jurisdiction.
2. My organization provides the necessary support for the PHA and DIO to achieve the goals in the ORS Action Plan.
3. Our public safety partner provides the necessary support for the PHA and DIO to achieve the goals in the ORS Action Plan.
4. Together, the ORS partners in my state/jurisdiction regularly share data, insights and trends we are seeing related to drug overdose in our communities.
	1. Agree: please provide specific examples in your state/jurisdiction from 2024.
	2. Disagree: Optional: Please elaborate on your selection.
5. Together, the ORS partners in my state/jurisdiction inform and help local communities develop local solutions to reduce overdoses and save lives.
	1. Agree: please provide specific examples in your state/jurisdiction from 2024.
	2. Disagree: Optional: Please elaborate on your selection.
6. Together, the ORS partners in my state/jurisdiction implement evidence-based response efforts that can directly reduce overdose deaths.
	1. Agree: please provide specific examples in your state/jurisdiction from 2024.
	2. Disagree: Optional: Please elaborate on your selection.
7. Together, the ORS partners in my state/jurisdiction design and use promising strategies at the intersection of public health and public safety.
	1. Agree: please provide specific examples in your state/jurisdiction from 2024.
	2. Disagree: Optional: Please elaborate on your selection.
8. Together, the ORS partners in my state/jurisdiction implement evidence-informed prevention strategies that can reduce substance use and overdose.
	1. Agree: please provide specific examples in your state/jurisdiction from 2024.
	2. Disagree: Optional: Please elaborate on your selection.
9. What communities experience a greater burden of overdose in your jurisdiction, and how has your ORS partnership worked to reduce these disparities?
10. How has your ORS partnership addressed social, structural, and systemic factors that impact substance use and overdose?
11. The ORS partners in my state/jurisdiction are doing a good job leveraging the strengths and assets of **public health** to reduce fatal and non-fatal overdoses.
	1. Agree: please describe specific strengths and assets used.
	2. Disagree: Optional: Please elaborate on your selection.
12. The ORS partners in my state/jurisdiction are doing a good job leveraging the strengths and assets of **public safety** to reduce fatal and non-fatal overdoses.
	1. Agree: please describe specific strengths and assets used.
	2. Disagree: Optional: Please elaborate on your selection.
13. My organization is making improved decisions about policies or programs and the use of resources to reduce fatal and non-fatal overdoses because of the ORS program.
	1. Agree:Please describe specific decisions made about policies and programs or use of resources.
	2. Disagree: Optional: Please elaborate on your selection.

**Impact of Partnership**

1. Looking back at 2024, what do you think was the most significant change in collaboration across public health and public safety in your jurisdiction as a result of your participation in the ORS?
2. What have been the most challenging aspects of this collaboration?
3. What suggestions or ideas do you have for improving collaboration between public health and public safety partners?
4. In what ways have overdose and related trends changed in the last year, if at all, as a result of public health-public safety partnership in your jurisdiction?
5. What about the ORS program has been the most impactful on your organization’s ability to contribute to the reduction of fatal and non-fatal overdoses?
6. Please describe a success story related to your collaboration with the ORS program in 2024. *Information you highlight may be featured anonymously in program communications.*
7. What is your vision for the future of the ORS program?
8. Is there any other feedback you would like to share? (optional)